ArticlePharmaceuticals (Basel, Switzerland)2020
Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.
Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 9 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.Respirology (Carlton, Vic.) · 2021Pooled it
- Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.Pharmacotherapy · 2021Pooled it
- Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.International journal of environmental research and public health · 2021Pooled it
- Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).Leukemia · 2021Pooled it
- The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7).Addiction (Abingdon, England) · 2021Pooled it
- Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.Expert review of clinical immunology · 2021Pooled it
- Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Pooled it
- Pooled it
- Munc13-4-STX7 inhibitors impair endosomal TLR activation and systemic inflammation.Nature chemical biology · 2026Article
- Mechanisms and clinical research progress of IL-6-mediated crosstalk between the alveolar microenvironment and the immune system in patients with severe pneumonia undergoing mechanical ventilation.Frontiers in immunology · 2026Review
- Article
- Translatability scoring in prospective and retrospective COVID drug development cases.European journal of clinical pharmacology · 2023Article
- Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence.Expert review of anti-infective therapy · 2022Article
- Biologics in COVID-19 So Far: Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.Journal of clinical immunology · 2022Article
- Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital.Research square · 2021Article
- Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis.Infectious diseases and therapy · 2021Article
- A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital.Journal of epidemiology and global health · 2021Observational
- Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis.World journal of methodology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted for severe COVID-19 pneumonia (SpO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.